Quest Diagnostics Inc

Quest Diagnostics: Market‑leading diagnostics, CLIA & CAP‑accredited testing, rapid TAT, patient‑centric growth, and solid earnings outlook.

Quest Diagnostics’ FY‑2024 report shows steady 6.3 % revenue growth, 11.8 % margin, and a 15 % ROIC on AI‑driven digital pathology, positioning it for strong 5.6 % FY‑2025 growth.

Quest Diagnostics’ trading snapshot reveals strong cash flow, value‑based revenue growth and strategic lab expansion, while tackling labor shortages, supply chain shocks and tech upgrades to stay ahead of reimbursement shifts.

Quest Diagnostics stays strong—boosting test volumes, cutting costs, and expanding into molecular diagnostics—while delivering solid returns and a solid valuation.

Quest Diagnostics reinforces its market lead at JPMorgan’s Healthcare Conference, boosting diagnostic‑analytics services and improving margins to drive future growth.

Quest Diagnostics joins the 44th J.P. Morgan Healthcare Conference to showcase its lab‑network expansion, data‑intelligence focus, and strategic plans for growth amid industry consolidation.

Insightful analysis of Quest Diagnostics insider sale, valuation, AI‑driven lab automation, and Medicare reimbursement risks – why investors should watch QDX closely.

Quest Diagnostics keeps expanding its U.S. lab network, grows revenue by 4% and maintains a 13% operating margin while investing in tech‑driven efficiencies and value‑based care.

Quest Diagnostics’ stable growth, FDA‑cleared tests, rapid turnaround and cost‑effective, evidence‑based diagnostics make it a trusted partner for U.S. clinicians and patients.

Quest Diagnostics is expected to report strong Q3 2025 earnings, driven by increased demand for its laboratory services and recent contracts with health-care payers, with analysts forecasting a substantial uptick in earnings per share.